Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of oral RV521 in hospitalized infants with RSV lower respiratory tract infection
MOH_2022-04-17_010272Phase 2Completed
- Sponsor
- ReViral
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sisunatovir in respiratory syncytial virus disease (RSV) and pulmonary infection (5 arms), sponsored by ReViral. Primary endpoint: Safety and tolerability of single and multiple oral doses of RV521. Started Apr 2022; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infection
Beyond the preview
Go deeper on MOH_2022-04-17_010272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-04-17_010272.